Meda Pharma




Meda Pharma
Concise Prescribing Info
Symptomatic treatment of OA, RA & ankylosing spondylitis, acute gouty arthritis, primary dysmenorrhea, post-op dental pain, post-op gynecological pain; chronic musculo-skeletal pain, including chronic low back pain.
Dosage/Direction for Use
OA 30 mg or 60 mg once daily. RA, ankylosing spondylitis & post-op dental pain 90 mg once daily. Chronic musculoskeletal pain, including chronic low back pain 60 mg once daily. Acute gouty arthritis & primary dysmenorrhea 120 mg once daily. Post-op gynecological pain 90 mg once daily; initial dose should be administered shortly before surgery. Max: 120 mg once daily. For acute pain conditions use for max of 8 days. Patients w/ mild hepatic insufficiency (Child-Pugh score 5-6) Max dose: 60 mg once daily. Moderate hepatic insufficiency (Child-Pugh score 7-9) Max dose: 60 mg every other day or 30 mg once daily.
May be taken with or without food.
Hypersensitivity. Moderate to severe heart failure (NYHA class II-IV); inadequately controlled HTN; ischemic heart disease; peripheral arterial disease &/or cerebrovascular disease; active peptic ulceration or GI bleeding; inflammatory bowel disease. Renal impairment (CrCl <30 mL/min).
Special Precautions
Contraindicated in hypersensitivity, pregnancy & lactation, patients recently undergone CABG surgery, CV & cerebrovascular disease, uncontrolled HTN, MI or CHF (NYHA II-IV), history of ischemic heart disease or paralysis from cerebrovascular disease. Caution in patients w/ risk factors of CV disease eg, HTN, hyperlipidemia, DM, smoking & elderly; hepatic & renal impairment. Discontinue at the 1st signs of hypersensitivity; persistently abnormal liver enzyme values. Should not be used in patients w/ ischemic heart disease, peripheral arterial or cerebrovascular disease. History or at risk of GI ulceration & bleeds. Avoid in severe hepatic impairment. Dehydrated patient; rehydrate patients before treatment.
Adverse Reactions
Discomfort, nausea, diarrhea, bleeding, ulceration; headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, anxiety, impaired mental acuity, paraesthesia, confusion, hallucinations; HTN, palpitation, atrial fibrillation, transient ischemic attack, chest pain; cough, dyspnea, epistaxis; renal failure; hepatic damage; rashes, angioedema, bronchospasm; fluid retention, hearing disturbances (tinnitus), visual disturbance, photosensitivity, haematuria, fatigue, myalgia, arthralgia, influenza-like symptoms, ecchymosis, dry mouth, taste disturbance, mouth ulcer, appetite, wt change, flushing, electrolyte disturbance.
Drug Interactions
May result changes in plasma conc w/ drug that are cytochrome P450 isozymes CYP3A4 inhibitors or inducers. Decreased plasma conc w/ rifampicin. Increase plasma conc of ethinylestradiol. Enhanced effects of oral anticoagulants & increased plasma conc of lithium, methotrexate & cardiac glycosides. Increased risk of nephrotoxicity w/ ACE inhibitors, ciclosporin, tacrolimus, or diuretics. Increased risk of hyperkalemia w/ ACE inhibitors & some diuretics eg, K-sparing diuretics. Increased risk of adverse effects w/ >1 NSAIDs including aspirin. Increased risk of GI bleeding & ulceration w/ corticosteroids, SSRIs, serotonin norepinephrine reuptake inhibitors (eg, venlafaxine), antiplatelets (eg, clopidogrel & ticlopidine), iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, or pentoxifylline.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Atulox FC tab 120 mg
3 × 10's
Atulox FC tab 60 mg
3 × 10's
Atulox FC tab 90 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in